Literature DB >> 17685383

Classification of eating disorders: toward DSM-V.

Denise E Wilfley1, Monica E Bishop, G Terence Wilson, W Stewart Agras.   

Abstract

OBJECTIVE: A goal of the DSM-IV revision is to increase clinical and research utility by improving diagnostic validity through reliance on empirical evidence. Currently defined eating disorder (ED) categories have limited validity and require refinement based on data.
METHOD: The available scientific evidence is considered in evaluating the current ED nosology.
RESULTS: Specific recommendations include modifying ED classification by retaining categories but adding a dimensional component; removing the amenorrhea criterion for anorexia nervosa (AN); removing the subtypes for AN and bulimia nervosa (BN); making binge eating disorder (BED) an official diagnosis; and unifying the frequency and duration cut-points for BN and BED to once per week for 3 months. Priority research areas should include epidemiologic studies of full-range ED symptomatology and should focus on empirical validation for individual criterion.
CONCLUSION: There are significant issues to address in revising ED nosology as we move toward a more valid and useful DSM-V. (c) 2007 by Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2007        PMID: 17685383     DOI: 10.1002/eat.20436

Source DB:  PubMed          Journal:  Int J Eat Disord        ISSN: 0276-3478            Impact factor:   4.861


  56 in total

1.  Stability and change in patterns of concerns related to eating, weight, and shape in young adult women: a latent transition analysis.

Authors:  Angela S Cain; Amee J Epler; Douglas Steinley; Kenneth J Sher
Journal:  J Abnorm Psychol       Date:  2010-05

2.  Who is really at risk? Identifying risk factors for subthreshold and full syndrome eating disorders in a high-risk sample.

Authors:  C Jacobi; E Fittig; S W Bryson; D Wilfley; H C Kraemer; C Barr Taylor
Journal:  Psychol Med       Date:  2011-01-31       Impact factor: 7.723

3.  Binge eating in surgical weight-loss treatments. Long-term associations with weight loss, health related quality of life (HRQL), and psychopathology.

Authors:  J de Man Lapidoth; A Ghaderi; C Norring
Journal:  Eat Weight Disord       Date:  2011-12       Impact factor: 4.652

4.  Heterogeneity moderates treatment response among patients with binge eating disorder.

Authors:  Robyn Sysko; Tom Hildebrandt; G Terence Wilson; Denise E Wilfley; W Stewart Agras
Journal:  J Consult Clin Psychol       Date:  2010-10

Review 5.  [Eating disorders associated with obesity and diabetes].

Authors:  S Munsch; S Herpertz
Journal:  Nervenarzt       Date:  2011-09       Impact factor: 1.214

6.  Impact of broadening definitions of anorexia nervosa on sample characteristics.

Authors:  Jocilyn E Dellava; Laura M Thornton; Paul Lichtenstein; Nancy L Pedersen; Cynthia M Bulik
Journal:  J Psychiatr Res       Date:  2010-10-24       Impact factor: 4.791

7.  A pilot study of personality pathology in patients with anorexia nervosa: modifiable factors related to outcome after hospitalization.

Authors:  L M McCormick; P K Keel; M C Brumm; D B Watson; V L Forman-Hoffman; W A Bowers
Journal:  Eat Weight Disord       Date:  2009 Jun-Sep       Impact factor: 4.652

8.  Effects of reducing the frequency and duration criteria for binge eating on lifetime prevalence of bulimia nervosa and binge eating disorder: implications for DSM-5.

Authors:  Sara E Trace; Laura M Thornton; Tammy L Root; Suzanne E Mazzeo; Paul Lichtenstein; Nancy L Pedersen; Cynthia M Bulik
Journal:  Int J Eat Disord       Date:  2011-08-31       Impact factor: 4.861

9.  Evaluation of the DSM-5 Severity Specifier for Bulimia Nervosa in Treatment-Seeking Youth.

Authors:  Antonios Dakanalis; Fabrizia Colmegna; Maria Assunta Zanetti; Ester Di Giacomo; Giuseppe Riva; Massimo Clerici
Journal:  Child Psychiatry Hum Dev       Date:  2018-02

Review 10.  Role of antiepileptic drugs in the management of eating disorders.

Authors:  Susan L McElroy; Anna I Guerdjikova; Brian Martens; Paul E Keck; Harrison G Pope; James I Hudson
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.